|
1
|
Marcus NJ: Pain in cancer patients
unrelated to the cancer or treatment. Cancer Invest. 23:84–93.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Williams AC and Craig KD: Updating the
definition of pain. Pain. 157:2420–2423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alcock MM: Defining pain: Past, present,
and future. Pain. 158:761–762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Izumi H, Igishi T, Yamasaki A, Takeda K,
Yanai M, Tanaka N, Sakamoto T, Nishii-Ito S, Touge H, Kodani M, et
al: Development of fever following first administration of
zoledronate as a prognostic factor in advanced non-small cell lung
cancer patients with bone metastases. Mol Clin Oncol. 7:1000–1004.
2017.PubMed/NCBI
|
|
5
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo Q, Xu Z, Wang L, Ruan M and Jin G:
Progress in the research on the mechanism of bone metastasis in
lung cancer. Mol Clin Oncol. 5:227–235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bell R: Efficacy of ibandronate in
metastatic bone disease: Review of clinical data. The oncologist.
10 (Suppl 1):S8–S13. 2005. View Article : Google Scholar
|
|
9
|
Fontanella C, Fanotto V, Rihawi K, Aprile
G and Puglisi F: Skeletal metastases from breast cancer:
Pathogenesis of bone tropism and treatment strategy. Clin Exp
Metastasis. 32:819–833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kolesnikov-Gauthier H, Lemoine N,
Tresch-Bruneel E, Olivier A, Oudoux A and Penel N: Efficacy and
safety of 153Sm-EDTMP as treatment of painful bone
metastasis: A large single-center study. Support Care Cancer.
26:751–758. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vardy J and Agar M: Nonopioid drugs in the
treatment of cancer pain. J Clin Oncol. 32:1677–1690. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aapro M, Abrahamsson PA, Body JJ, Coleman
RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, et al:
Guidance on the use of bisphosphonates in solid tumours:
Recommendations of an international expert panel. Ann Oncol.
19:420–432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Idota A, Sawaki M, Yoshimura A, Hattori M,
Inaba Y, Oze I, Kikumori T, Kodera Y and Iwata H: Bone Scan Index
predicts skeletal-related events in patients with metastatic breast
cancer. Springerplus. 5:10952016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pavlakis N, Schmidt R and Stockler M:
Bisphosphonates for breast cancer. Cochrane Database Syst Rev.
CD003474. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Small EJ, Smith MR, Seaman JJ, Petrone S
and Kowalski MO: Combined analysis of two multicenter, randomized,
placebo-controlled studies of pamidronate disodium for the
palliation of bone pain in men with metastatic prostate cancer. J
Clin Oncol. 21:4277–4284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coleman RE: Bisphosphonates: Clinical
experience. Oncologist. 9 (Suppl 4):S14–S27. 2004. View Article : Google Scholar
|
|
17
|
Rosen LS, Gordon D, Kaminski M, Howell A,
Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma
DJ, et al: Long-term efficacy and safety of zoledronic acid
compared with pamidronate disodium in the treatment of skeletal
complications in patients with advanced multiple myeloma or breast
carcinoma: A randomized, double-blind, multicenter, comparative
trial. Cancer. 98:1735–1744. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wardley A, Davidson N, Barrett-Lee P, Hong
A, Mansi J, Dodwell D, Murphy R, Mason T and Cameron D: Zoledronic
acid significantly improves pain scores and quality of life in
breast cancer patients with bone metastases: A randomised,
crossover study of community vs hospital bisphosphonate
administration. Br J Cancer. 92:1869–1876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shapiro CL, Moriarty JP, Dusetzina S,
Himelstein AL, Foster JC, Grubbs SS, Novotny PJ and Borah BJ:
Cost-effectiveness analysis of monthly zoledronic acid, zoledronic
acid every 3 months, and monthly denosumab in women with breast
cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin
Oncol. 35:3949–3955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shapiro CL and Himelstein AL: Zoledronic
acid dosing in patients with metastatic breast cancer. JAMA Oncol.
4:585–586. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Himelstein AL, Loprinzi CL and Shapiro CL:
Zoledronic acid dosing interval for metastatic cancer-reply. JAMA.
317:14782017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Himelstein AL, Foster JC, Khatcheressian
JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS,
O'Connor T, et al: Effect of longer-interval vs standard dosing of
zoledronic acid on skeletal events in patients with bone
metastases: A randomized clinical trial. JAMA. 317:48–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
von Moos R, Costa L, Ripamonti CI, Niepel
D and Santini D: Improving quality of life in patients with
advanced cancer: Targeting metastatic bone pain. Eur J Cancer.
71:80–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burton AW and Cleeland CS: Cancer pain:
Progress since the WHO guidelines. Pain Pract. 1:236–242. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Varrassi G, Müller-Schwefe G, Pergolizzi
J, Orónska A, Morlion B, Mavrocordatos P, Margarit C, Mangas C,
Jaksch W, Huygen F, et al: Pharmacological treatment of chronic
pain-the need for CHANGE. Curr Med Res Opin. 26:1231–1245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lara-Solares A, Ahumada Olea M, Basantes
Pinos ALÁ, Bistre Cohén S, Bonilla Sierra P, Duarte Juárez ER,
Símon Escudero OA, Santacruz Escudero JG and Flores Cantisani JA:
Latin-American guidelines for cancer pain management. Pain Manag.
7:287–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshimoto T, Tomiyasu S, Saeki T, Tamaki
T, Hashizume T, Murakami M and Matoba M;: Symptom Control Research
Group (SCORE-G): How do hospital palliative care teams use the WHO
guidelines to manage unrelieved cancer pain? A 1-year, multicenter
audit in Japan. Am J Hosp Palliat Care. 34:92–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martínez-Nicolás I, Ángel-García D,
Saturno PJ and López-Soriano F: Cancer pain management: Systematic
review and critical appraisal of clinical practice guidelines. Rev
Calid Asist. 31:55–63. 2016.(In Spanish). View Article : Google Scholar
|
|
29
|
Carlson CL: Effectiveness of the World
Health Organization cancer pain relief guidelines: An integrative
review. J Pain Res. 9:515–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sloan PA, Donnelly MB, Schwartz RW and
Sloan DA: Cancer pain assessment and management by housestaff.
Pain. 67:475–481. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warncke T, Breivik H and Vainio A:
Treatment of cancer pain in Norway. A questionnaire study. Pain.
57:109–116. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paice JA, Toy C and Shott S: Barriers to
cancer pain relief: Fear of tolerance and addiction. J Pain Symptom
Manage. 16:1–9. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miaskowski C, Dodd MJ, West C, Paul SM,
Tripathy D, Koo P and Schumacher K: Lack of adherence with the
analgesic regimen: A significant barrier to effective cancer pain
management. J Clin Oncol. 19:4275–4279. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caraceni A, Martini C, Zecca E, Portenoy
RK, Ashby MA, Hawson G, Jackson KA, Lickiss N, Muirden N, Pisasale
M, et al: Breakthrough pain characteristics and syndromes in
patients with cancer pain. An international survey. Palliat Med.
18:177–183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gustorff B, Dorner T, Likar R, Grisold W,
Lawrence K, Schwarz F and Rieder A: Prevalence of self-reported
neuropathic pain and impact on quality of life: A prospective
representative survey. Acta Anaesthesiol Scand. 52:132–136. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piano V, Verhagen S, Schalkwijk A, Burgers
J, Kress H, Treede RD, Hekster Y, Lanteri-Minet M, Engels Y and
Vissers K: Diagnosing neuropathic pain in patients with cancer:
Comparative analysis of recommendations in national guidelines from
European countries. Pain Pract. 13:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pergolizzi JV Jr, Raffa RB, Zampogna G,
Breve F, Colucci R, Schmidt WK and LeQuang JA: Comments and
suggestions from pain specialists regarding the CDC's proposed
opioid guidelines. Pain Pract. 16:794–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dueñas M, Salazar A, Sanchez M, De Sola H,
Ojeda B and Failde I: Relationship between using clinical practice
guidelines for pain treatment and physicians' training and
attitudes toward patients and the effects on patient care. Pain
Pract. 18:38–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Skorpen F, Laugsand EA, Klepstad P and
Kaasa S: Variable response to opioid treatment: Any genetic
predictors within sight? Palliat Med. 22:310–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sakai K, Matsuoka H, Ohtake Y, Makimura C,
Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K and
Koyama A: Incidence of carnitine deficiency in patients with cancer
pain: A pilot study. Mol Clin Oncol. 6:331–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Scarborough BM and Smith CB: Optimal pain
management for patients with cancer in the modern era. CA Cancer J
Clin. 68:182–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Azevedo LF, Costa PA, Dias C, Agualusa L,
Lemos L, Romão J, Patto T, Vaz-Serra S, Abrunhosa R, Carvalho CJ,
et al: Tradução, adaptação cultural e estudo multicêntrico de
validação de instrumentos para rastreio e avaliação do impacto da
dor crónica. Dor. 15:6–56. 2007.
|
|
43
|
Cleeland CS and Ryan KM: Pain assessment:
Global use of the brief pain inventory. Ann Acad Med Singapore.
23:129–138. 1994.PubMed/NCBI
|
|
44
|
Cleeland CS, O'Mara A, Zagari M and Baas
C: Integrating pain metrics into oncology clinical trials. Clin
Cancer Res. 17:6646–6650. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Basch E, Dueck AC, Rogak LJ, Minasian LM,
Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett
E, et al: Feasibility assessment of patient reporting of
symptomatic adverse events in multicenter cancer clinical trials.
JAMA Oncol. 3:1043–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jadad AR and Browman GP: The WHO analgesic
ladder for cancer pain management. Stepping up the quality of its
evaluation. JAMA. 274:1870–1873. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pergolizzi J, Böger RH, Budd K, Dahan A,
Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB and
Sacerdote P: Opioids and the management of chronic severe pain in
the elderly: Consensus statement of an international expert panel
with focus on the six clinically most often used World Health
Organization Step III opioids (buprenorphine, fentanyl,
hydromorphone, methadone, morphine, oxycodone). Pain Pract.
8:287–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Canser E, Martinez-Serrano B, Sancho A,
Alonso-Babarro A, Vilches Y, Alonso-Yanci E, Gredilla E and Gilsanz
F: Invasive techniques for pain management in palliative care: A
single center experience. Pain Pract. 14:632–639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
van Kleef M, Mekhail N and van Zundert J:
Evidence-based guidelines for interventional pain medicine
according to clinical diagnoses. Pain Pract. 9:247–251. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Likar R, Krainer B and Sittl R:
Challenging the equipotency calculation for transdermal
buprenorphine: Four case studies. Int J Clin Pract. 62:152–156.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cleeland CS: The measurement of pain from
metastatic bone disease: Capturing the patient's experience. Clin
Cancer Res. 12:6236s–6242s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Serlin RC, Mendoza TR, Nakamura Y, Edwards
KR and Cleeland CS: When is cancer pain mild, moderate or severe?.
Grading pain severity by its interference with function. Pain.
61:277–284. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
P F, : Criação da Versão Portuguesa do MOS
SF-36, Parte II-Testes de validação. Acta Med Port. 13:119–127.
2000.PubMed/NCBI
|
|
55
|
Dénommé F, Kroemer M, Montcuquet P, Nallet
G, Thiery-Vuillemin A, Bazan F, Mouillet G, Villanueva C, Demarchi
M, Stein U, et al: Prevalence and management of pain in patients
with metastatic cancer in Franche-Comté. Bull Cancer. 103:849–860.
2016.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
56
|
van den Beuken-van Everdingen MH, de Rijke
JM, Kessels AG, Schouten HC, van Kleef M and Patijn J: Prevalence
of pain in patients with cancer: A systematic review of the past 40
years. Ann Oncol. 18:1437–1449. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Castro C, Antunes L, Lunet N and Bento MJ:
Cancer incidence predictions in the North of Portugal: Keeping
population-based cancer registration up to date. Eur J Cancer Prev.
25:472–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Trama A, Foschi R, Larrañaga N, Sant M,
Fuentes-Raspall R, Serraino D, Tavilla A, Van Eycken L and Nicolai
N;: EUROCARE-5 Working Group: Survival of male genital cancers
(prostate, testis and penis) in Europe 1999–2007: Results from the
EUROCARE-5 study. Eur J Cancer. 51:2206–2216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pina F, Castro C, Ferro A, Bento MJ and
Lunet N: Prostate cancer incidence and mortality in Portugal:
Trends, projections and regional differences. Eur J Cancer Prev.
26:404–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sant M, Chirlaque Lopez MD, Agresti R,
Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos
K, Katalinic A, Langseth H, et al: Survival of women with cancers
of breast and genital organs in Europe 1999–2007: Results of the
EUROCARE-5 study. Eur J Cancer. 51:2191–2205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Paice JA, Portenoy R, Lacchetti C,
Campbell T, Cheville A, Citron M, Constine LS, Cooper A, Glare P,
Keefe F, et al: Management of chronic pain in survivors of adult
cancers: American society of clinical oncology clinical practice
guideline. J Clin Oncol. 34:3325–3345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huber MB, Felix J, Vogelmann M and Leidl
R: Health-related quality of life of the general german population
in 2015: Results from the EQ-5D-5L. Int J Environ Res Public
Health. 14(pii): E4262017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Santoro GC, Carrion J, Patel K, Vilchez C,
Veith J, Brodie JD and Dewey SL: Sex differences in regional brain
glucose metabolism following opioid withdrawal and replacement.
Neuropsychopharmacology. 42:1841–1849. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lami MJ, Martinez MP, Sánchez AI, Miró E,
Diener FN, Prados G and Guzmán MA: Gender differences in patients
with fibromyalgia undergoing cognitive-behavioral therapy for
insomnia: Preliminary data. Pain Pract. 16:E23–E34. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Suzuki N, Mashu S, Toyoda M and Nishibori
M: Oral burning sensation: Prevalence and gender differences in a
Japanese population. Pain Pract. 10:306–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kong P, Yan J, Liu D, Ji Y, Wang Y, Zhuang
J, Wang J, Hu X and Yue X: Skeletal-related events and overall
survival of patients with bone metastasis from nonsmall cell lung
cancer-A retrospective analysis. Medicine (Baltimore).
96:e93272017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dworkin RH, Turk DC, Wyrwich KW, Beaton D,
Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD,
Ader DN, et al: Interpreting the clinical importance of treatment
outcomes in chronic pain clinical trials: IMMPACT recommendations.
J Pain. 9:105–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zylla D, Kuskowski MA, Gupta K and Gupta
P: Association of opioid requirement and cancer pain with survival
in advanced non-small cell lung cancer. Br J Anaesth. 113 (Suppl
1):i109–i116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zylla D, Steele G and Gupta P: A
systematic review of the impact of pain on overall survival in
patients with cancer. Support Care Cancer. 25:1687–1698. 2017.
View Article : Google Scholar : PubMed/NCBI
|
